C
ENTA icon

Covestor’s Enanta Pharmaceuticals ENTA Stock Holding History

Covestor’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
7
-8
-53% -$107 ﹤0.01% 2384
2025
Q4 		$0 Sell
15
-1
-6% -$13 ﹤0.01% 2371
2025
Q3 		$0 Hold
16
– – ﹤0.01% 2396
2025
Q2 		$0 Sell
16
-1
-6% -$6 ﹤0.01% 2338
2025
Q1 		$0 Buy
17
+13
+325% +$80 ﹤0.01% 2350
2024
Q4 		$0 Hold
4
– – ﹤0.01% 2356
2024
Q3 		$0 Hold
4
– – ﹤0.01% 2346
2024
Q2 		$0 Hold
4
– – ﹤0.01% 2357
2024
Q1 		$0 Sell
4
-1
-20% -$13 ﹤0.01% 2357
2023
Q4 		$0 Hold
5
– – ﹤0.01% 2269
2023
Q3 		$0 Buy
5
+1
+25% +$16 ﹤0.01% 2245
2023
Q2 		$0 Buy
4
+1
+33% +$29 ﹤0.01% 2257
2023
Q1 		$0 Hold
3
– – ﹤0.01% 2159
2022
Q4 		$0 Sell
3
-1
-25% -$46 ﹤0.01% 2188
2022
Q3 		$0 Buy
4
+1
+33% +$58 ﹤0.01% 2135
2022
Q2 		$0 Sell
3
-2
-40% -$109 ﹤0.01% 2029
2022
Q1 		$0 Sell
5
-1
-17% -$65 ﹤0.01% 2196
2021
Q4 		$0 Buy
+6
New +$471 ﹤0.01% 2169

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Covestor's ENTA Position: Q1 2026 in Review

Covestor reduced its Enanta Pharmaceuticals (ENTA) stake by 53% in Q1 2026, selling an estimated $107 and leaving 7 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2384.

Covestor first reported a position in ENTA in Q4 2021 and has held it in 18 quarters since. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Covestor held 7 shares of Enanta Pharmaceuticals worth $0 as of Q1 2026.
  • Covestor sold 8 Enanta Pharmaceuticals shares in Q1 2026, an estimated $107.
  • Enanta Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2384 holding.
  • Covestor first reported a position in Enanta Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.